Advances in therapy
-
Advances in therapy · Jan 2018
Randomized Controlled Trial Multicenter StudyOnce-Daily Triple Therapy in Patients with COPD: Patient-Reported Symptoms and Quality of Life.
Directly recorded patient experience of symptoms and health-related quality of life (HRQoL) can complement lung function and exacerbation rate data in chronic obstructive pulmonary disease (COPD) clinical studies. The FULFIL study recorded daily symptoms and activity limitation together with additional patient-reported outcomes of dyspnea and HRQoL, as part of the prespecified analyses. FULFIL co-primary endpoint data have been previously reported. ⋯ These findings demonstrate sustained daily symptom and HRQoL benefits of FF/UMEC/VI versus BUD/FOR. The inclusion of the CAT may provide data that are readily generalizable to everyday clinical practice.
-
Advances in therapy · Jan 2018
ReviewReview of Post-Marketing Safety Data on Tapentadol, a Centrally Acting Analgesic.
Tapentadol is a centrally acting analgesic that has been available for the management of acute and chronic pain in routine clinical practice since 2009. ⋯ Grünenthal GmbH.